Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.66 |
| ▸ | NAMPT | P43490 | 12/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361473 | 0.83 | HTT (0.67) | MEN1KMT2ANAMPTL3MBTL1POLB | |
| SCHEMBL23747749 | 0.83 | HTT (0.67) | MEN1KMT2ANAMPTL3MBTL1POLB | |
| SCHEMBL20379359 | 0.79 | NAMPT (0.85) | MEN1KMT2ANAMPTL3MBTL1POLB | |
| SCHEMBL30361432 | 0.79 | NAMPT (0.73) | MEN1KMT2ANAMPTL3MBTL1POLB | |
| SCHEMBL23747489 | 0.79 | NAMPT (0.73) | MEN1KMT2ANAMPTL3MBTL1POLB | |
| SCHEMBL166801 | 0.78 | NAMPT (0.82) | NAMPT | |
| SCHEMBL29635672 | 0.78 | NAMPT (0.82) | NAMPT | |
| SCHEMBL29635770 | 0.78 | NAMPT (1.00) | NAMPT | |
| SCHEMBL166369 | 0.78 | NAMPT (1.00) | NAMPT | |
| SCHEMBL30361447 | 0.77 | NAMPT (0.70) | NAMPTL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | claimed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | claimed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | claimed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | NAMPT, NAPRT, NNT | MEN1 1269/4885KMT2A 1672/4885PABPC1 1205/4885 |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | MEN1 4160/4885KMT2A 3000/4885PABPC1 2777/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | MEN1 4160/4885KMT2A 3000/4885PABPC1 2777/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | MEN1 4160/4885KMT2A 3000/4885PABPC1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.